Zobrazeno 1 - 10 of 137 pro vyhledávání: '"Stanford L, Peng"'
1
Akademický článek
A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults
Autor: Rupert Davies, Stanford L. Peng, Jason Lickliter, Kristi McLendon, Amanda Enstrom, Allison G. Chunyk, Lori Blanchfield, NingXin Wang, Tiffany Blair, Heather M. Thomas, Alina Smith, Stacey R. Dillon
Publikováno v: Clinical and Translational Science, Vol 17, Iss 11, Pp n/a-n/a (2024)
Abstract Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B‐cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune disease
Externí odkaz: https://doaj.org/article/25b4a1e71e8b46e2abae51f6db9f5445
Zobrazit plný text záznamu
2
Akademický článek
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
Autor: Amanda Enstrom, Diwakar Davar, Nehal Lakhani, Heidi LeBlanc, Stanford L Peng, Frank Schneider, Heather Thomas, Michael J Chisamore, Allison Naumovski, Ludimila Cavalcante, Sreenivasa Chandana, Joseph Schmalz, Krisztina Lengyel
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Engagement of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can interfere with the CD28 signaling requisite for T-cell activation. While immune checkpoint inhibitors (ICIs) can relieve this suppression, they are u
Externí odkaz: https://doaj.org/article/c9c952f6909f45a9bac6077e91d171b3
Zobrazit plný text záznamu
3
Akademický článek
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
Autor: Mark Voskoboynik, Justin Moser, Mario Sznol, Amita Patnaik, Amanda Enstrom, Diwakar Davar, Michael Millward, Rachel E Sanborn, Meredith McKean, Justin F Gainor, Nehal Lakhani, Heidi LeBlanc, Stanford L Peng, Heather Thomas, Lori Blanchfield, Michael J Chisamore, Allison Naumovski, Ludimila Cavalcante, Jaspreet S Grewal, Ajita Narayan
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Davoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain designed to mediate programmed death-ligand 1 (PD-L1)-dependent CD28 co-stimulation while inhibiting the PD-L1 and cytotoxic T-lymphocyte-associated antigen 4
Externí odkaz: https://doaj.org/article/09d04456db2341698a183766d4d11533
Zobrazit plný text záznamu
5
Akademický článek
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
Autor: Mark F. Maurer, Katherine E. Lewis, Joseph L. Kuijper, Dan Ardourel, Chelsea J. Gudgeon, Siddarth Chandrasekaran, Sherri L. Mudri, Kayla N. Kleist, Chris Navas, Martin F. Wolfson, Mark W. Rixon, Ryan Swanson, Stacey R. Dillon, Steven D. Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T. Logan, Björn Walse, Kristine M. Swiderek, Stanford L. Peng
Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
CD28 costimulatory signalling can be suppressed by immune checkpoints, such as CTLA-4 and PD-1. Here the authors describe the design of the fusion therapeutic davoceticept (ALPN-202), based on a variant CD80 extracellular domain engineered to bind PD
Externí odkaz: https://doaj.org/article/1c1e0e459c4147429eef80ef95841f04
Zobrazit plný text záznamu
6
Akademický článek
First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects
Autor: Jing Yang, Jason D. Lickliter, Jan L. Hillson, Gary D. Means, Russell J. Sanderson, Kay Carley, Almudena Tercero, Kristi L. Manjarrez, Jennifer R. Wiley, Stanford L. Peng
Publikováno v: Clinical and Translational Science, Vol 14, Iss 4, Pp 1314-1326 (2021)
Abstract ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator
Externí odkaz: https://doaj.org/article/701f4101ee394f428fca2532c07f1b57
Zobrazit plný text záznamu
7
Akademický článek
Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains
Autor: Steven D. Levin, Lawrence S. Evans, Susan Bort, Erika Rickel, Katherine E. Lewis, Rebecca P. Wu, Joseph Hoover, Sean MacNeil, David La, Martin F. Wolfson, Mark W. Rixon, Stacey R. Dillon, Michael G. Kornacker, Ryan Swanson, Stanford L. Peng
Publikováno v: Frontiers in Immunology, Vol 10 (2020)
Immunoglobulin superfamily member (IgSF) proteins play a significant role in regulating immune responses with surface expression on all immune cell subsets, making the IgSF an attractive family of proteins for therapeutic targeting in human diseases.
Externí odkaz: https://doaj.org/article/bed901c0bf43422ba8dc0a6914b60717
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje